CN113712206A - A composition containing folium Mori DNJ and folium Mori peptide and its preparation method - Google Patents
A composition containing folium Mori DNJ and folium Mori peptide and its preparation method Download PDFInfo
- Publication number
- CN113712206A CN113712206A CN202111086475.3A CN202111086475A CN113712206A CN 113712206 A CN113712206 A CN 113712206A CN 202111086475 A CN202111086475 A CN 202111086475A CN 113712206 A CN113712206 A CN 113712206A
- Authority
- CN
- China
- Prior art keywords
- mulberry leaf
- dnj
- peptide
- parts
- folium mori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 81
- 240000000249 Morus alba Species 0.000 claims abstract description 81
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 16
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000227 grinding Methods 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- 235000013325 dietary fiber Nutrition 0.000 claims description 8
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 108091005658 Basic proteases Proteins 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 238000001471 micro-filtration Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 101710166469 Endoglucanase Proteins 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000037221 weight management Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 108010059892 Cellulase Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 238000004260 weight control Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 241000776601 Fissistigma oldhamii Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a composition containing mulberry leaf DNJ and mulberry leaf peptide and a preparation method thereof, belonging to the technical field of health-care food, wherein the composition containing the mulberry leaf DNJ and the mulberry leaf peptide comprises the following components in parts by weight: 3-6 parts of mulberry leaf DNJ, 2-4 parts of mulberry leaf peptide and 0.5-3 parts of auxiliary materials; the composition containing the mulberry leaf DNJ and the mulberry leaf peptide is beneficial to absorbing oil in vivo and preventing the absorption of fat and carbohydrate, thereby being beneficial to losing weight and reducing fat rate, improving beneficial intestinal flora in vivo, being used for weight management and having no side effect after long-term administration; solves the problem of products which are lacked in the current market and can safely and healthily control the weight.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a composition containing mulberry leaf DNJ and mulberry leaf peptide and a preparation method thereof.
Background
With the improvement of living standard, the dietary structure of people is changed greatly, and the type of the high-grain diet is changed into the type of three-high, so that various chronic diseases, such as diabetes, cardiovascular diseases, intestinal diseases, obesity and the like, caused by the change also have great influence on the life of people.
Generally, obesity is a result of the combined action of various factors such as diet, lifestyle, genetic characteristics, social factors and the like, and is closely related to energy absorption and metabolism, fat synthesis, in vivo oxidative stress, intestinal flora and the like. At present, the medicines for controlling energy in the market mainly comprise pancrelipase inhibitor orlistat and appetite inhibitor sibutramine, but the medicines have large toxic and side effects and can cause harm to human bodies after long-term use. Meanwhile, natural plants are increasingly entering the visual field of people for treating obesity with better safety and certain effectiveness, and are accepted by more people. Moreover, many practices prove that the weight control method is a safe, efficient and economic weight control method by means of natural plant products. Therefore, the market lacks a green, safe and healthy product formula capable of controlling weight.
Disclosure of Invention
The invention aims to solve the technical problem of providing a composition containing mulberry leaf DNJ and mulberry leaf peptide extracted and separated from Fissistigma Oldhamii.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a composition containing mulberry leaf DNJ and mulberry leaf peptide comprises the following components in parts by weight:
3-6 parts of mulberry leaf DNJ, 2-4 parts of mulberry leaf peptide and 0.5-3 parts of auxiliary materials.
As a further scheme of the invention: the paint comprises the following components in parts by weight:
5 parts of mulberry leaf DNJ, 3 parts of mulberry leaf peptide and 2 parts of auxiliary materials.
As a further scheme of the invention: the auxiliary materials comprise isomaltose hypgather and dietary fiber.
As a further scheme of the invention: the preparation method of the mulberry leaf DNJ comprises the following steps:
extracting folium Mori with water to obtain water extract, and collecting folium Mori residue;
microfiltering and ultrafiltering the water extraction product to obtain a low-content DNJ extracting solution;
subjecting the DNJ extract with low content to ion exchange resin column, eluting with water and ammonia water sequentially to obtain ammonia water eluate containing DNJ with high content;
and (3) concentrating and spray-drying ammonia water eluent containing high-content DNJ to obtain mulberry leaf DNJ powder.
As a further scheme of the invention: the preparation method of the mulberry leaf peptide comprises the following steps:
grinding the mulberry leaf dregs into pulp by a grinding machine;
adding mixed enzyme into the slurry, uniformly mixing by using a stirrer, and carrying out enzymolysis to obtain an enzymolysis solution;
heating the enzymolysis liquid to 100 ℃, inactivating the enzyme for 10 minutes, and carrying out rough filtration, microfiltration and ultrafiltration on the inactivated enzymolysis liquid to obtain micromolecular mulberry leaf peptide liquid;
concentrating and spray drying the small molecular mulberry leaf peptide liquid to obtain mulberry leaf peptide powder.
As a further scheme of the invention: the mixed enzyme comprises neutral protease, alkaline protease and cellulase.
The preparation method of the composition containing mulberry leaf DNJ and mulberry leaf peptide comprises the following steps:
mixing the mulberry leaf DNJ, the mulberry leaf peptide, the isomaltooligosaccharide and the dietary fiber according to a proportion to obtain the product.
Compared with the prior art, the invention has the beneficial effects that: the composition containing the mulberry leaf DNJ and the mulberry leaf peptide is beneficial to absorbing oil in vivo and preventing the absorption of fat and carbohydrate, thereby being beneficial to losing weight, reducing fat rate, improving beneficial intestinal flora in vivo, being used for weight management and having no side effect after long-term administration.
Drawings
FIG. 1 is a graph showing the change of body weight of rats in different groups with time.
Detailed Description
Example 1
Extracting folium Mori with water to obtain water extract, and collecting folium Mori residue;
microfiltering and ultrafiltering the water extraction product to obtain a low-content DNJ extracting solution;
subjecting the DNJ extract with low content to ion exchange resin column, eluting with water and ammonia water sequentially to obtain ammonia water eluate containing DNJ with high content;
and (3) concentrating and spray-drying ammonia water eluent containing high-content DNJ to obtain mulberry leaf DNJ powder.
Grinding the mulberry leaf dregs into pulp by a grinding machine;
adding mixed enzyme into the pulp, wherein the mixed enzyme comprises the following components in a mass ratio of 1: 1:1, uniformly mixing the neutral protease, the alkaline protease and the cellulase by using a stirrer, controlling the temperature to be 35 ℃, and performing enzymolysis for 2 hours to obtain an enzymolysis solution;
heating the enzymolysis liquid to 100 ℃, inactivating the enzyme for 10 minutes, and carrying out rough filtration, microfiltration and ultrafiltration on the inactivated enzymolysis liquid to obtain micromolecular mulberry leaf peptide liquid;
concentrating and spray drying the small molecular mulberry leaf peptide liquid to obtain mulberry leaf peptide powder.
300g of mulberry leaf DNJ powder, 400g of mulberry leaf peptide powder, 25g of isomaltooligosaccharide and 25g of dietary fiber are mixed to obtain the composition.
Example 2
Extracting folium Mori with water to obtain water extract, and collecting folium Mori residue;
microfiltering and ultrafiltering the water extraction product to obtain a low-content DNJ extracting solution;
subjecting the DNJ extract with low content to ion exchange resin column, eluting with water and ammonia water sequentially to obtain ammonia water eluate containing DNJ with high content;
and (3) concentrating and spray-drying ammonia water eluent containing high-content DNJ to obtain mulberry leaf DNJ powder.
Grinding the mulberry leaf dregs into pulp by a grinding machine;
adding mixed enzyme into the pulp, wherein the mixed enzyme comprises the following components in a mass ratio of 1: 1:1, uniformly mixing the neutral protease, the alkaline protease and the cellulase by using a stirrer, controlling the temperature to be 35 ℃, and performing enzymolysis for 2 hours to obtain an enzymolysis solution;
heating the enzymolysis liquid to 100 ℃, inactivating the enzyme for 10 minutes, and carrying out rough filtration, microfiltration and ultrafiltration on the inactivated enzymolysis liquid to obtain micromolecular mulberry leaf peptide liquid;
concentrating and spray drying the small molecular mulberry leaf peptide liquid to obtain mulberry leaf peptide powder.
600g of mulberry leaf DNJ powder, 200g of mulberry leaf peptide powder, 150g of isomaltooligosaccharide and 150g of dietary fiber are mixed to obtain the composition.
Example 3
Extracting folium Mori with water to obtain water extract, and collecting folium Mori residue;
microfiltering and ultrafiltering the water extraction product to obtain a low-content DNJ extracting solution;
subjecting the DNJ extract with low content to ion exchange resin column, eluting with water and ammonia water sequentially to obtain ammonia water eluate containing DNJ with high content;
and (3) concentrating and spray-drying ammonia water eluent containing high-content DNJ to obtain mulberry leaf DNJ powder.
Grinding the mulberry leaf dregs into pulp by a grinding machine;
adding mixed enzyme into the pulp, wherein the mixed enzyme comprises the following components in a mass ratio of 1: 1:1, uniformly mixing the neutral protease, the alkaline protease and the cellulase by using a stirrer, controlling the temperature to be 35 ℃, and performing enzymolysis for 2 hours to obtain an enzymolysis solution;
heating the enzymolysis liquid to 100 ℃, inactivating the enzyme for 10 minutes, and carrying out rough filtration, microfiltration and ultrafiltration on the inactivated enzymolysis liquid to obtain micromolecular mulberry leaf peptide liquid;
concentrating and spray drying the small molecular mulberry leaf peptide liquid to obtain mulberry leaf peptide powder.
The composition is prepared by mixing 500g folium Mori DNJ powder, 300g folium Mori peptide powder, 100g isomaltooligosaccharide and 100g dietary fiber.
Experimental verification
The effect of the composition sample prepared in example 3 (mulberry leaf DNJ: mulberry leaf peptide: isomaltooligosaccharide: dietary fiber: 5:3:1:1) on weight control was studied using a high-sugar high-fat diet-induced rat obesity model.
Selecting 72 SD male rats, and adaptively feeding for 7 days; after the adaptation period, the cells were randomly divided into 6 groups according to body weight, and blood (inner canthus or tail of eye) was collected to separate serum, and the levels of TC, TG and LDL-C, HDL-C in serum were measured. The first group of rats was given normal feed as a blank control group (Cotrol); the rats of the second group were fed with high calorie feed as a Model group (Model), the rats of the third group were fed with high calorie feed while orlistat was fed as a positive control group (ASLT), the rats of the fourth group were fed with high calorie feed while test samples of the high dose composition were gavaged as a high dose group (KZ-H), the rats of the fifth group were fed with high calorie feed while test samples of the low dose composition were gavaged as a low dose group (KZ-L), the rats of the sixth group were fed with test samples of the composition mixed with high calorie feed (KZ-B), the daily feeding amount was determined based on the feed consumption of the day before the blank control group in terms of 0.8g/(kg.d), and the feeding time was 35 days. The diet, diet amount, and food remaining amount were recorded daily for each group, and the body weight was weighed 1 time per week.
The effect on body weight, the results are shown in figure 1: the experimental results show that the body weight of each group before administration has no significant difference, and the body weight difference of each group after administration for one week begins to be obvious. By week 3, the body weights of the ASLT, KZ-L, KZ-H and KZ-B groups were all significantly lower than the blank control group. From week 4 until week 7, body weights of ASLT, KZ-L, KZ-H and KZ-B groups were significantly lower than those of the blank control group and the model group (P < 0.01). In addition, the body weight of the KZ-B group was significantly lower than that of the ASLT group. These results indicate that the composition of the present invention comprising mulberry DNJ and mulberry peptide has the effect of inhibiting weight gain caused by high calorie feeding.
The effect on blood glucose, the results are shown in table 1: the results of the experiments show that the diabetic model cannot be reproduced after the high-calorie feed is fed, and the blood sugar level in the blood of each group except the KZ-B group is basically maintained at a normal level. The blood glucose levels in the KZ-B group were significantly decreased compared to the normal group (P < 0.05).
TABLE 1
The results of the effect on blood lipids are shown in table 2: the experimental result shows that after the feed is fed by the high-sugar high-fat feed for 7 weeks, the total triglyceride level of the model group is obviously higher than that of the blank control group (P is less than 0.05), and the total cholesterol, the low-density lipoprotein and the high-density lipoprotein of the model group have no significant difference compared with the blank control group, which indicates that the high-sugar high-fat feed can enable the total triglyceride level of the serum of the rat to have certain influence, but is not enough to cause hyperlipidemia; and has little influence on serum cholesterol index of high-sugar and high-fat feed. In addition, the total triglyceride levels of the three ASLT, KZ-H and KZ-L groups were also very significantly increased compared to the blank control group (P <0.05), indicating that the composition prepared in the present invention had no significant effect on the serum total triglyceride levels. In addition, these three groups also had no significant effect on serum cholesterol levels. However, the serum total triglyceride level of the KZ-B group has no significant difference compared with the blank control group, and the total cholesterol, the low density lipoprotein and the high density lipoprotein in the group have very significant changes compared with the blank control group and the model group.
TABLE 2
| Group of | TG(mmol/L) | TCH(mmol/L) | LDL(mmol/L) | HDL-HC(mmol/L) |
| Blank control group | 0.16±0.14 | 1.49±0.23 | 0.69±0.10 | 0.15±0.04 |
| Model set | 0.87±0.17* | 1.39±0.17 | 0.67±0.13 | 0.18±0.05 |
| ASLT | 1.02±0.25** | 1.56±0.34 | 0.88±0.34 | 0.19±0.05 |
| KZ-H | 0.92±0.14** | 1.67±0.22 | 0.94±0.10 | 0.22±0.06 |
| KZ-L | 1.12±0.19** | 1.61±0.16 | 0.78±0.11 | 0.21±0.05 |
| KZ-B | 0.64±0.09 | 2.64±0.26**## | 1.44±0.33**## | 0.45±0.06**## |
Very significant difference compared to normal group (P < 0.05); very significant difference compared to normal group (P <0.01) and # very significant difference compared to model group (P < 0.01).
In summary, the following steps: the composition containing the mulberry leaf DNJ and the mulberry leaf peptide has the effects of inhibiting weight gain caused by high-calorie feeding, is beneficial to absorbing oil in vivo and preventing absorption of fat and carbohydrate, is beneficial to losing weight, reducing fat rate, improving beneficial intestinal flora in vivo, can be used for weight management, and has no side effect after long-term administration.
Claims (7)
1. A composition containing mulberry leaf DNJ and mulberry leaf peptide is characterized by comprising the following components in parts by weight:
3-6 parts of mulberry leaf DNJ, 2-4 parts of mulberry leaf peptide and 0.5-3 parts of auxiliary materials.
2. The mulberry leaf DNJ and mulberry leaf peptide-containing composition according to claim 1, which comprises the following components in parts by weight:
5 parts of mulberry leaf DNJ, 3 parts of mulberry leaf peptide and 2 parts of auxiliary materials.
3. The mulberry leaf DNJ and mulberry leaf peptide-containing composition according to claim 2, wherein the auxiliary materials comprise isomaltooligosaccharide and dietary fiber.
4. The composition containing mulberry leaf DNJ and mulberry leaf peptide as claimed in claim 1, wherein the preparation method of mulberry leaf DNJ is as follows:
extracting folium Mori with water to obtain water extract, and collecting folium Mori residue;
microfiltering and ultrafiltering the water extraction product to obtain a low-content DNJ extracting solution;
subjecting the DNJ extract with low content to ion exchange resin column, eluting with water and ammonia water sequentially to obtain ammonia water eluate containing DNJ with high content;
and (3) concentrating and spray-drying ammonia water eluent containing high-content DNJ to obtain mulberry leaf DNJ powder.
5. The composition of claim 3, wherein the mulberry leaf peptide is prepared by the following steps:
grinding the mulberry leaf dregs into pulp by a grinding machine;
adding mixed enzyme into the slurry, uniformly mixing by using a stirrer, and carrying out enzymolysis to obtain an enzymolysis solution;
heating the enzymolysis liquid to 100 ℃, inactivating the enzyme for 10 minutes, and carrying out rough filtration, microfiltration and ultrafiltration on the inactivated enzymolysis liquid to obtain micromolecular mulberry leaf peptide liquid;
concentrating and spray drying the small molecular mulberry leaf peptide liquid to obtain mulberry leaf peptide powder.
6. The mulberry leaf DNJ and mulberry leaf peptide-containing composition of claim 4, wherein the mixed enzyme comprises neutral protease, alkaline protease and cellulase.
7. A method for preparing the mulberry leaf DNJ and mulberry leaf peptide-containing composition according to any one of claims 1 to 6, comprising the steps of:
mixing the mulberry leaf DNJ, the mulberry leaf peptide, the isomaltooligosaccharide and the dietary fiber according to a proportion to obtain the product.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111086475.3A CN113712206A (en) | 2021-09-16 | 2021-09-16 | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method |
| PCT/CN2021/126330 WO2023040001A1 (en) | 2021-09-16 | 2021-10-26 | Composition containing mori folium dnj and mori folium peptide, and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111086475.3A CN113712206A (en) | 2021-09-16 | 2021-09-16 | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113712206A true CN113712206A (en) | 2021-11-30 |
Family
ID=78684089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111086475.3A Pending CN113712206A (en) | 2021-09-16 | 2021-09-16 | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113712206A (en) |
| WO (1) | WO2023040001A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602411A (en) * | 2023-06-02 | 2023-08-18 | 广东省农业科学院蚕业与农产品加工研究所 | Composition for regulating intestinal flora, and preparation method and application thereof |
| CN116602412A (en) * | 2023-06-02 | 2023-08-18 | 广东省农业科学院蚕业与农产品加工研究所 | Constipation-resistant composition, and preparation method and application thereof |
| CN116762958A (en) * | 2023-06-16 | 2023-09-19 | 广州市科贝思生物技术有限公司 | Mulberry leaf extract and preparation method and application thereof |
| CN117547025A (en) * | 2024-01-12 | 2024-02-13 | 北京新浠芮生物技术有限公司 | Composition for controlling weight as well as preparation method and application thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030224087A1 (en) * | 2002-04-13 | 2003-12-04 | Lee Young Jik | Chewing gum including ingredients of mulberrry leaf |
| US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
| US20080187606A1 (en) * | 2001-12-12 | 2008-08-07 | Min-Young Kim | Antiobesity composition |
| CN103564104A (en) * | 2013-10-15 | 2014-02-12 | 江苏科技大学 | Method for preparing hypotensive mulberry leaf tea bag |
| CN105148252A (en) * | 2015-08-19 | 2015-12-16 | 湖南博佰生物科技有限公司 | Compound blood glucose reducing preparation |
| CN106912920A (en) * | 2015-12-28 | 2017-07-04 | 天津中新药业研究中心 | A kind of composition containing mulberry-leaf extract and application thereof |
| CN107119097A (en) * | 2017-05-23 | 2017-09-01 | 华南理工大学 | A kind of mulberry leaf immune-active peptides and preparation method thereof |
| CN107177655A (en) * | 2017-06-05 | 2017-09-19 | 深圳知本康业有限公司 | A kind of protein of folium mori polypeptide and application |
| CN108635408A (en) * | 2018-08-09 | 2018-10-12 | 劲牌生物医药有限公司 | A kind of mulberry-leaf extract and preparation method thereof, application and health liquor |
| JP2019127439A (en) * | 2018-01-22 | 2019-08-01 | 株式会社お茶村 | Supplement comprising morus alba leaves |
| CN110951810A (en) * | 2019-12-27 | 2020-04-03 | 湖北瑞邦生物科技有限公司 | High-activity mulberry leaf oligopeptide powder extraction process |
| CN111533680A (en) * | 2020-05-28 | 2020-08-14 | 成都医学院 | Folium Mori extract and folium Mori multicomponent mixture with blood sugar lowering effect prepared from the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105272988B (en) * | 2015-11-09 | 2017-11-28 | 上海天伟纺织质量技术服务有限公司 | A kind of pool extracting method of mulberry leaf active ingredient |
| IT201700032960A1 (en) * | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | NUTRACEUTICAL COMPOUND FOR THE TREATMENT OF THE EXCESS OF WEIGHT AND MODERATE HYPERCOLESTEROLEMIA AND DISGLICEMIA |
| US10702487B2 (en) * | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| CN111345422A (en) * | 2018-12-21 | 2020-06-30 | 中粮营养健康研究院有限公司 | Solid beverage with synergistic blood sugar reducing effect and preparation and eating method thereof |
| CN112587648A (en) * | 2020-02-05 | 2021-04-02 | 河北康平健康产业有限责任公司 | Bitter gourd peptide composition for preventing and treating diabetes and preparation method thereof |
-
2021
- 2021-09-16 CN CN202111086475.3A patent/CN113712206A/en active Pending
- 2021-10-26 WO PCT/CN2021/126330 patent/WO2023040001A1/en unknown
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080187606A1 (en) * | 2001-12-12 | 2008-08-07 | Min-Young Kim | Antiobesity composition |
| US20030224087A1 (en) * | 2002-04-13 | 2003-12-04 | Lee Young Jik | Chewing gum including ingredients of mulberrry leaf |
| US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
| CN103564104A (en) * | 2013-10-15 | 2014-02-12 | 江苏科技大学 | Method for preparing hypotensive mulberry leaf tea bag |
| CN105148252A (en) * | 2015-08-19 | 2015-12-16 | 湖南博佰生物科技有限公司 | Compound blood glucose reducing preparation |
| CN106912920A (en) * | 2015-12-28 | 2017-07-04 | 天津中新药业研究中心 | A kind of composition containing mulberry-leaf extract and application thereof |
| CN107119097A (en) * | 2017-05-23 | 2017-09-01 | 华南理工大学 | A kind of mulberry leaf immune-active peptides and preparation method thereof |
| CN107177655A (en) * | 2017-06-05 | 2017-09-19 | 深圳知本康业有限公司 | A kind of protein of folium mori polypeptide and application |
| JP2019127439A (en) * | 2018-01-22 | 2019-08-01 | 株式会社お茶村 | Supplement comprising morus alba leaves |
| CN108635408A (en) * | 2018-08-09 | 2018-10-12 | 劲牌生物医药有限公司 | A kind of mulberry-leaf extract and preparation method thereof, application and health liquor |
| CN110951810A (en) * | 2019-12-27 | 2020-04-03 | 湖北瑞邦生物科技有限公司 | High-activity mulberry leaf oligopeptide powder extraction process |
| CN111533680A (en) * | 2020-05-28 | 2020-08-14 | 成都医学院 | Folium Mori extract and folium Mori multicomponent mixture with blood sugar lowering effect prepared from the same |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602411A (en) * | 2023-06-02 | 2023-08-18 | 广东省农业科学院蚕业与农产品加工研究所 | Composition for regulating intestinal flora, and preparation method and application thereof |
| CN116602412A (en) * | 2023-06-02 | 2023-08-18 | 广东省农业科学院蚕业与农产品加工研究所 | Constipation-resistant composition, and preparation method and application thereof |
| CN116762958A (en) * | 2023-06-16 | 2023-09-19 | 广州市科贝思生物技术有限公司 | Mulberry leaf extract and preparation method and application thereof |
| CN117547025A (en) * | 2024-01-12 | 2024-02-13 | 北京新浠芮生物技术有限公司 | Composition for controlling weight as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023040001A1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113712206A (en) | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method | |
| CN103283837A (en) | Guava fermented red bean milk with cosmetic effect | |
| CN101180998A (en) | Gold vinegar tea beverage and manufacturing technology | |
| CN110122865B (en) | Infant auxiliary food added with breast milk oligosaccharide and preparation method thereof | |
| CN102250731A (en) | Raw materials of health preserving white spirit, dendrobium health preserving white spirit and manufacturing method thereof | |
| CN104146300A (en) | Compound Noni juice and preparation method thereof | |
| CN117158579A (en) | Application of black matrimony vine fermented product with alopecia preventing effect | |
| CN101642176A (en) | Method for preparing wild jujube honey tea for relieving neurasthenia | |
| CN101971881B (en) | Red date diglyceride micro milk beverage and preparation method thereof | |
| CN110973423A (en) | Red yeast noni beverage and preparation method thereof | |
| CN102669682B (en) | Selenium-enriched nutrient yeast food and production method thereof | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN110862897A (en) | Mulberry leaf and silkworm chrysalis yellow wine and its making process | |
| CN111972659A (en) | Meal replacement powder for chia seed Chinese yam | |
| CN107625018A (en) | A kind of preparation method of fermented ginger leaf beverage | |
| CN107259523A (en) | The careless ferment of one kind file | |
| CN105614178A (en) | Mixed feed special for tilapia overwintering and preparation method thereof | |
| CN110150388B (en) | Almond red date composite protein beverage and preparation method thereof | |
| CN109874960B (en) | Preparation process of bee pollen crystal | |
| CN113498838A (en) | Honey refined tangerine peel and tangerine juice paste and preparation method thereof | |
| CN102342406A (en) | Medicinal and edible total nutrient diet composition and manufacturing method | |
| CN1079194C (en) | Chromium-riched whole-wheat convalescence flour and its production | |
| CN107557243B (en) | Mixed brewed Nuomei melon wine and preparation method thereof | |
| CN103468511A (en) | Preparation method for maca daqu liquor | |
| KR20190135805A (en) | Method of fermented red ginseng with enhanced Compound-K and Rh2 content by the comnined strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211130 |